Ware J. Anthony 4

What Happened

• Director Ware J. Anthony was granted multiple equity awards on April 20, 2026 in connection with First Tracks Biotherapeutics’ spin-off from AnaptysBio. The grants total 141,615 shares (reported as derivative awards) and were reported at an acquisition price of $0. These awards include outright common stock from the spin-off, adjusted stock options, and restricted stock units (RSUs).

Key Details

• Transaction date: April 20, 2026. Form 4 filed April 22, 2026 (timely within the usual two-business-day reporting window).
• Total shares/awards reported: 141,615 shares acquired via awards/grants. Reported price: $0 (no cash paid on grant).
• Transaction code: A (award/grant); reported as derivative securities (options/RSUs) in the filing.
• Shares owned after transaction: Not specified in the provided extract of the Form 4.
• Important footnotes from the filing:
  • F1: Some shares are common stock received in the spin-off from AnaptysBio.
  • F2–F4: Certain awards are adjustments of pre-existing AnaptysBio stock options into First Tracks options; some options are fully vested (F3) and some vest monthly (1/12 per month beginning Feb 6, 2026) (F4).
  • F5–F8: Some awards are RSUs (each convertible to one share on settlement). RSUs were adjusted from AnaptysBio RSUs (F6) and have vesting dates tied to the issuer’s 2026 or 2027 annual meetings (F7, F8).
• No indication in the filing that shares were sold immediately (no cashless exercise or open-market sale reported).

Context

• These are grant/adjustment transactions tied to a corporate separation (spin-off). That means several pre-existing AnaptysBio awards were split/adjusted so that the holder now has separate awards for First Tracks and for AnaptysBio.
• Because most items are options/RSUs and were granted at $0, there was no cash purchase or sale — these are not immediate buy/sell signals. Vesting schedules and settlement conditions will determine when shares become transferable or taxable.